Mumbai: Wanbury Ltd., a pharmaceutical company with a presence in the global API market and domestic branded formulations, has announced its financial results for the quarter ended 30th June, 2025.
Financial Highlights:
For the quarter ended as on 31st March 2025:
- Revenue from operations for Q1FY26 stood at ₹163.2 crore, up from ₹131.1 crore in Q1FY25, reflecting a strong YoY growth of 24%. This growth was driven by higher sales volumes in key API products such as Sertraline, supported by increased production capacity, as well as strong sales performance in the Branded Formulations segment
- EBITDA (including other income) for the quarter stood at ₹24.8 crore, compared to ₹11.9 crore in Q1FY25, registering a growth of 108%. This performance was driven by operating leverage and backward integration of key API products such as Sertraline
- PAT for the quarter stood at ₹13.5 crore, compared to ₹1.0 crore in Q1FY25, registering a growth of 1198%. This improvement was primarily driven by strong growth in Revenue and EBITDA during the quarter
Commenting on the performance, Mohan Rayana, Director of Wanbury Ltd., said, “Q1 FY26 marks a strong recovery for Wanbury, with both manufacturing facilities operating at healthy capacity levels post last year’s planned upgradation. This has positively impacted our top line and profitability, setting a strong tone for the year ahead. The Board has also approved ₹85 crore CAPEX plan for FY26, the investments will commence towards a new production block for new APIs, product yield and solvent recovery improvements, and capacity enhancement initiatives. In regard to the recent US tariff measures, Wanbury has only a limited exposure to the US market, which currently accounts for nearly 15% of our export revenues. This continued resilience supports our focus on operational excellence and innovation to drive growth in regulated markets.”
